Département de Pharmacologie, Université Bordeaux Segalen, INSERM U657, BP 36, 33076 Bordeaux, France.
Drug Saf. 2013 Jul;36(7):565-72. doi: 10.1007/s40264-013-0063-5.
In spontaneous reporting databases, reports of well-established drug-event associations may mask alerts that arise from other drugs (drug competition bias). However, a symmetrical event-competition bias has not yet been explored whereby known events may mask an association with new events for a given drug or drug class.
The objective of this study was to explore the effects of event-competition bias on safety signals generated from spontaneous reporting databases.
The drug classes tested included statins, oral anticoagulants, antipsychotics and HIV antiretrovirals. For each, a type A reaction was selected, and its potential competitive effect on the generation of other safety signals for the drug was explored. These were rhabdomyolysis/myopathy for statins, haemorrhage for oral anticoagulants, extrapyramidal syndrome for antipsychotics and lipodystrophy for HIV antiretrovirals. Signals of disproportionate reporting (SDRs) were detected using the case/non-case approach in the French research spontaneous reporting database (which contains reports from 1 January 1986 to 31 December 2001), before and after removing all reports concerning these competitor events. SDRs were considered as potential signals if not reported in the literature before 1 January 2002 but confirmed since.
The whole database included 207,236 reports, 4,355 of which included statins as one of the suspected drugs. The removal of reports of rhabdomyolysis/myopathy concerned 8,425 reports among which 867 involved statins. After this removal, 11 new SDRs appeared for statins that had not been detected initially. Similarly, 15 SDRs were unmasked for oral anticoagulants, six for antipsychotics and nine for HIV antiretrovirals. After literature-based assessment, five of the 41 unmasked SDRs appeared related to potential safety signals confirmed after 2002.
This study demonstrated that a masking phenomenon resulting from an event-competition effect could occur when performing signal detection using disproportionality analyses of spontaneous reporting databases. This should be taken into account when routine signal detection is performed.
在自发报告数据库中,已确立的药物-事件关联的报告可能会掩盖其他药物引起的警报(药物竞争偏差)。然而,尚未探索到对称的事件竞争偏差,即已知事件可能掩盖给定药物或药物类别与新事件之间的关联。
本研究旨在探讨事件竞争偏差对自发报告数据库中安全性信号产生的影响。
所测试的药物类别包括他汀类药物、口服抗凝剂、抗精神病药和 HIV 抗逆转录病毒药物。对于每一种药物,选择一种 A 型反应,并探讨其对药物其他安全性信号产生的潜在竞争影响。这些反应分别是他汀类药物的横纹肌溶解/肌病、口服抗凝剂的出血、抗精神病药的锥体外系综合征和 HIV 抗逆转录病毒药物的脂肪营养不良。使用病例/非病例方法在法国研究自发报告数据库(包含 1986 年 1 月 1 日至 2001 年 12 月 31 日期间的报告)中检测到比例性报告(SDR),然后在去除所有涉及这些竞争事件的报告后再次进行检测。如果在 2002 年 1 月 1 日之前文献中没有报道,但此后得到证实,则认为 SDR 是潜在信号。
整个数据库包含 207236 份报告,其中 4355 份报告包含他汀类药物作为一种可疑药物。横纹肌溶解/肌病报告的去除涉及 8425 份报告,其中 867 份涉及他汀类药物。去除后,最初未检测到的他汀类药物出现了 11 个新的 SDR。类似地,口服抗凝剂、抗精神病药和 HIV 抗逆转录病毒药物分别有 15、6 和 9 个 SDR 被揭示。基于文献的评估后,在 41 个未被揭示的 SDR 中,有 5 个与 2002 年后确认的潜在安全性信号有关。
本研究表明,在使用自发报告数据库的比例性分析进行信号检测时,可能会出现由于事件竞争效应导致的掩盖现象。在进行常规信号检测时应考虑到这一点。